{
  "abstract": "Background\n\nImmunoglobulin isotype is recorded at diagnosis in every patient with intact-immunoglobulin multiple myeloma, but is not retained in the ISS, R-ISS, or R2-ISS.Methods\n\nWe analyzed 196 consecutive patients with IgA or IgG myeloma who underwent upfront autologous stem cell transplantation at a single center (2009-2023). The primary endpoint was progression-free survival (PFS); overall survival (OS) was the secondary endpoint. Cox models used information available at transplantation, including the induction regimen and transplant year, in the complete-case set (n = 131) and after multiple imputation (n = 196).Results\n\nMedian PFS was 14.8 versus 30.5 months and OS 43.2 versus 94.2 months in IgA versus IgG patients (both p < 0.001). IgA isotype was associated with inferior PFS (adjusted HR 1.85, 95% CI 1.13-3.02; imputed HR 1.83, 95% CI 1.22-2.73). For OS, the HR was 1.68 (0.98-2.88) in the complete-case analysis and 1.91 (1.24-2.94) after imputation, so its magnitude is uncertain. Models with maintenance gave 1.87 and 1.82. Progression documentation differed by maintenance status. Cytogenetic data were too incomplete to assess independence from genomic risk.Conclusions\n\nIn a bortezomib-era transplant cohort, IgA isotype was associated with inferior PFS; the association with OS was of uncertain magnitude. The finding is hypothesis-generating and requires validation in cohorts with complete cytogenetic characterization.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology, Bursa Şehir Training & Research Hospital, University of Health Sciences, 16250 Bursa, Türkiye.",
    "Department of Internal Medicine, Bursa Şehir Training & Research Hospital, University of Health Sciences, 16250 Bursa, Türkiye.",
    "Department of Hematology, Ali Osman Sönmez Oncology Hospital, 16020 Bursa, Türkiye.",
    "Department of Hematology, Bursa Uludağ University Hospital, Bursa Uludağ University, 16059 Bursa, Türkiye."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Tuba Güllü Koca"
    },
    {
      "affs": [
        1
      ],
      "name": "Nizameddin Koca",
      "orcid": "0000-0003-1457-4366"
    },
    {
      "affs": [
        0
      ],
      "name": "Fazıl Çağrı Hunutlu"
    },
    {
      "affs": [
        0
      ],
      "name": "Ahmet Mert Yanık",
      "orcid": "0000-0002-1908-0149"
    },
    {
      "affs": [
        2
      ],
      "name": "Sinem Çubukçu"
    },
    {
      "affs": [
        3
      ],
      "name": "Rümeysa Yılmaz",
      "orcid": "0009-0005-0000-9122"
    },
    {
      "affs": [
        3
      ],
      "name": "Tuba Ersal",
      "orcid": "0000-0001-5419-3221"
    },
    {
      "affs": [
        3
      ],
      "name": "Vildan Gürsoy",
      "orcid": "0000-0002-3645-9345"
    },
    {
      "affs": [
        3
      ],
      "name": "İbrahim Ethem Pınar",
      "orcid": "0000-0001-9907-1498"
    },
    {
      "affs": [
        3
      ],
      "name": "Vildan Özkocaman"
    },
    {
      "affs": [
        3
      ],
      "name": "Fahir Özkalemkaş",
      "orcid": "0000-0001-9710-134X"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7try77tb52wts.bib",
  "cited_by": 0,
  "doi": "10.3390/cancers18193178",
  "fulltext_url": "https://europepmc.org/articles/PMC13664181",
  "id": "7try77tb52wts",
  "issns": [
    "2072-6694"
  ],
  "landing_url": "https://europepmc.org/article/MED/42882872",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2720|Multiple Myeloma Research and Treatments"
    ]
  ],
  "openalex": "W7216339521",
  "pdf_url": "https://europepmc.org/articles/PMC13664181?pdf=render",
  "pmcid": "PMC13664181",
  "pmid": "42882872",
  "published": "2026-10-02",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/7try77tb52wts.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:00Z",
      "native_id": "MED:42882872",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42882872"
    },
    {
      "first_seen": "2026-10-30T12:19:58Z",
      "native_id": "10.3390/cancers18193178",
      "source": "crossref",
      "url": "https://www.mdpi.com/2072-6694/18/19/3178"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2072-6694",
      "subfield": "oncology"
    }
  ],
  "title": "Immunoglobulin A Subtype and Survival After Upfront Autologous Stem Cell Transplantation in Multiple Myeloma: A Real-World Cohort from the Bortezomib Era.",
  "title_text": "Immunoglobulin A Subtype and Survival After Upfront Autologous Stem Cell Transplantation in Multiple Myeloma: A Real-World Cohort from the Bortezomib Era.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:58Z",
  "url": "https://research.draconitic.com/paper/7try77tb52wts",
  "venue": "Cancers",
  "versions": []
}